Dr. Houston is President and Chief Executive Officer of Arvinas. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments. He was also the site head of the BMS Connecticut facility. Dr. Houston was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late stage clinical trials, and toward commercialization.
He was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS which oversaw the design and implementation of an industry-leading integrated lead discovery and optimization process. This initiative created revolutionary changes in the discovery process at BMS with significant improvements in capacity, speed and cost control resulting in marked increases in research productivity and success rates.
Dr. Houston has over 28 years of experience in the pharmaceutical industry. Prior to joining Bristol-Myers Squibb, he worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston currently serves on the boards of directors of NextCure, Inc., Oerth Bio, Cybrexa Therapeutics and BioCT.
Dr. Houston obtained his B.Sc. degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. He also completed his post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.
What is John G. Houston's net worth?
The estimated net worth of John G. Houston is at least $12.18 million as of February 27th, 2026. Dr. Houston owns 1,122,183 shares of Arvinas stock worth more than $12,175,686 as of April 5th. This net worth estimate does not reflect any other investments that Dr. Houston may own. Learn More about John G. Houston's net worth.
How do I contact John G. Houston?
Has John G. Houston been buying or selling shares of Arvinas?
John G. Houston has not been actively trading shares of Arvinas over the course of the past ninety days. Most recently, John G. Houston sold 35,297 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $13.21, for a transaction totalling $466,273.37. Following the completion of the sale, the director now directly owns 1,122,183 shares of the company's stock, valued at $14,824,037.43. Learn More on John G. Houston's trading history.
Who are Arvinas' active insiders?
Arvinas' insider roster includes Noah Berkowitz (Chief Medical Officer), Sean Cassidy (CFO), John Houston (CEO), David Loomis (CAO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Andrew Saik (Chief Financial Officer and Treasurer), Timothy Shannon (Director), Ian Taylor (Insider), and Randy Teel (CEO). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?
In the last year, Arvinas insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $495,100.00. In the last year, insiders at the sold shares 10 times. They sold a total of 69,794 shares worth more than $848,094.43. The most recent insider tranaction occured on March, 18th when insider Noah Berkowitz sold 6,435 shares worth more than $71,428.50. Insiders at Arvinas own 4.7% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 3/18/2026.
